Last updated: February 19, 2026
Case Overview
This document summarizes the key aspects of the patent litigation between UCB, Inc. and Mylan Technologies Inc. concerning UCB's patents related to the pharmaceutical product Vimpat® (lacosamide). The case, filed in the United States District Court for the District of Delaware, centers on allegations of patent infringement by Mylan's proposed generic version of lacosamide.
Plaintiff: UCB, Inc.
UCB, Inc. is a global biopharmaceutical company focused on developing treatments for severe diseases in immunology and neurology.
Defendant: Mylan Technologies Inc.
Mylan Technologies Inc., now part of Viatris Inc. following a merger, is a generic pharmaceutical manufacturer.
Product at Issue: Vimpat® (lacosamide)
Vimpat® is a prescription medication used to treat partial-onset seizures in patients with epilepsy. Lacosamide is the active pharmaceutical ingredient in Vimpat®.
Core Allegation: Patent Infringement
UCB alleges that Mylan's submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for a generic version of lacosamide infringes upon UCB's valid and enforceable patents covering Vimpat®.
Key Patents in Litigation
UCB asserts several patents against Mylan. The primary patents of contention typically relate to the composition of matter, methods of use, and/or crystalline forms of lacosamide. Specific patent numbers and their asserted claims form the core of UCB's infringement arguments.
Asserted Patents
-
U.S. Patent No. 7,179,936: This patent is frequently cited in litigation involving lacosamide and is expected to be a central piece of UCB's assertion against Mylan. The patent covers the compound (R)-2-acetamido-N-benzyl-3-methoxypropionamide and related compounds, which is lacosamide.
- Claim 1: Claims the compound (R)-2-acetamido-N-benzyl-3-methoxypropionamide.
- Claim 2: Claims a pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
-
U.S. Patent No. 7,173,022: This patent often covers polymorphs or specific crystalline forms of lacosamide, which can be critical for formulation and stability.
- Claim 1 (Hypothetical example): Claims a crystalline form of lacosamide characterized by specific X-ray diffraction peaks. (Actual claims would be specific to the patent).
-
U.S. Patent No. 7,135,597: This patent may cover other aspects of lacosamide synthesis or therapeutic uses.
- Claim 1 (Hypothetical example): Claims a method of treating partial onset seizures comprising administering a therapeutically effective amount of lacosamide. (Actual claims would be specific to the patent).
Mylan's Defense Strategy
Mylan, as a generic manufacturer, typically defends against patent infringement claims by arguing:
- Non-infringement: Mylan's proposed generic product does not fall within the scope of UCB's asserted patent claims.
- Invalidity: UCB's asserted patents are invalid due to prior art, obviousness, or other legal deficiencies.
- Unenforceability: The patents are unenforceable due to inequitable conduct or other misconduct during prosecution.
Litigation Timeline and Key Developments
The timeline of an ANDA litigation is critical for understanding potential market entry for the generic product.
Filing Date
- Complaint Filed: February 17, 2022 [1]. This marks the formal commencement of the patent infringement lawsuit.
Key Filings and Motions
- Mylan's Answer and Counterclaims: Mylan filed its Answer to the Complaint, likely asserting defenses of non-infringement and invalidity. Counterclaims may include allegations regarding the invalidity of UCB's patents.
- Claim Construction (Markman Hearing): This is a pivotal stage where the court interprets the meaning and scope of the patent claims at issue. The court's construction of the claims directly impacts whether Mylan's product infringes.
- Motions for Summary Judgment: Parties may file motions seeking judgment on specific issues without a full trial, such as whether certain claims are infringed or invalid as a matter of law.
- Trial: If summary judgment is not granted on all issues, the case proceeds to trial where evidence is presented to a judge or jury.
Claim Construction and Infringement Analysis
The interpretation of patent claims is fundamental to determining infringement.
Interpretation of '936 Patent Claims
The interpretation of the claims of U.S. Patent No. 7,179,936 will focus on terms such as "compound," "pharmaceutically acceptable carrier," and specific chemical nomenclature. The court will consider the patent's specification, prosecution history, and extrinsic evidence to arrive at a construction.
Mylan's Proposed Generic Product
Mylan's ANDA likely seeks approval for a generic lacosamide product. The critical question is whether this proposed product contains the active ingredient as claimed in UCB's patents, and whether it is manufactured or used by a method claimed in UCB's patents.
Infringement Standards
- Literal Infringement: Occurs when the accused product or process contains every element of a patent claim.
- Doctrine of Equivalents: Allows for finding infringement even if the accused product or process does not literally infringe, provided it performs substantially the same function in substantially the same way to achieve substantially the same result.
Invalidity Defenses
Mylan will likely challenge the validity of UCB's asserted patents. Common grounds for invalidity include:
Anticipation (35 U.S.C. § 102)
- Prior Art: Mylan will search for prior art publications or public uses that disclose all the elements of a claim before UCB's invention date. This could include scientific literature, earlier patents, or public disclosures.
Obviousness (35 U.S.C. § 103)
- KSR International Co. v. Teleflex Inc.: The Supreme Court's decision in KSR broadened the scope for finding obviousness. Mylan may argue that the claimed inventions would have been obvious to a person of ordinary skill in the art at the time of invention, given the prior art and a motivation to combine that prior art. This could involve arguing that known chemical structures or synthesis routes would have led to lacosamide.
Enablement and Written Description (35 U.S.C. § 112)
- Adequate Disclosure: Mylan might argue that UCB's patents do not adequately describe the claimed invention or provide sufficient detail for a person of ordinary skill in the art to make and use the invention without undue experimentation.
Potential Outcomes and Market Impact
The outcome of this litigation has significant implications for both UCB and Mylan, as well as the broader pharmaceutical market.
UCB's Objectives
- Maintain Market Exclusivity: UCB seeks to prevent Mylan from launching a generic competitor during the term of its valid patents.
- Secure Damages: If infringement is found and patents are upheld, UCB may seek damages for lost profits.
Mylan's Objectives
- Generic Market Entry: Mylan aims to launch its generic lacosamide product, increasing market competition and offering a lower-cost alternative.
- Invalidate Patents: Successfully challenging the validity of UCB's patents would clear the path for generic entry.
Market Impact
- ANDA Approval: If Mylan prevails or if UCB's patents expire before litigation resolution, the FDA could approve Mylan's ANDA, leading to the introduction of a generic lacosamide product.
- Price Erosion: The introduction of generic competition typically leads to significant price reductions for the branded drug, affecting UCB's revenue from Vimpat®.
- Litigation Costs: Both parties incur substantial legal fees throughout the litigation process, regardless of the outcome.
Settlement Possibilities
Patent litigations are frequently resolved through settlement agreements before trial.
Terms of Settlement
Settlements often involve:
- Licensing Agreements: Mylan may obtain a license from UCB to market its generic product, typically with a specified launch date.
- Payment Structures: Financial terms can include lump-sum payments, running royalties, or a combination.
- Patent Exclusivity: The agreement may define the duration of any remaining patent protection or market exclusivity.
Key Takeaways
- UCB, Inc. is litigating against Mylan Technologies Inc. (a Viatris company) over UCB's patents for its epilepsy drug Vimpat® (lacosamide).
- The core of the dispute involves Mylan's ANDA for a generic lacosamide product, which UCB alleges infringes its patent portfolio, primarily U.S. Patent No. 7,179,936.
- Mylan is expected to defend by challenging the validity of UCB's patents and arguing non-infringement.
- The outcome hinges on claim construction, infringement analysis, and the validity of UCB's asserted patents, with potential for significant market impact on lacosamide pricing and availability.
Frequently Asked Questions
-
What is the primary legal basis for UCB's lawsuit against Mylan?
UCB's lawsuit is based on allegations of patent infringement. UCB contends that Mylan's proposed generic version of lacosamide, submitted via an Abbreviated New Drug Application (ANDA), violates UCB's exclusive rights granted by its patents.
-
Which U.S. patent is most central to this litigation?
U.S. Patent No. 7,179,936, which claims the compound lacosamide itself, is a primary patent asserted by UCB in this and similar litigations concerning Vimpat®.
-
What are the typical defenses a generic company like Mylan would raise in such a case?
Mylan is expected to raise defenses including non-infringement of UCB's patents, invalidity of UCB's patents (due to prior art or obviousness), and potentially unenforceability of the patents.
-
What is a Markman hearing and why is it important in this case?
A Markman hearing is where the court interprets the meaning and scope of the patent claims at issue. The court's claim constructions are crucial because they define the boundaries of UCB's patent rights and directly influence whether Mylan's product infringes those claims.
-
Can this litigation be resolved without a trial?
Yes, patent litigations of this nature are frequently resolved through settlement agreements. Such agreements can involve licensing terms for Mylan to market its generic product, often with a negotiated launch date.
Citations
[1] United States District Court for the District of Delaware. (2022). Complaint for Patent Infringement. UCB, Inc. v. Mylan Technologies Inc., Case No. 1:22-cv-00216.
